Intelligent Pulmonary Rehabilitation After Lung Cancer Surgery

NCT07631520 | Not Yet Recruiting

• 1 other identifier: ES-2025-266-27
• Study Type: interventional
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study will compare an intelligent pulmonary function exercise device with usual care and natural recovery in patients recovering from lung cancer surgery. After lung cancer surgery, many patients have reduced lung function, shortness of breath, lower exercise tolerance, and a risk of postoperative pulmonary complications. Standard care usually includes postoperative nursing, pain control, coughing and sputum clearance instruction, early mobilization, discharge education, and routine follow-up. However, patients often lack structured guidance, feedback, and monitoring after discharge. Participants in this study will be randomly assigned to one of two groups. One group will use an intelligent pulmonary function exercise device for respiratory training during hospitalization and at home until 30 days after surgery. The prescribed training is two sessions per day, with each session including 30 expiratory training repetitions and 30 inspiratory training repetitions. The device records training completion and related training information and provides reminders and feedback. The other group will receive usual perioperative care, standard discharge education, and natural recovery follow-up without a study-specified respiratory training device or training prescription. The main purpose of the study is to determine whether the intelligent pulmonary function exercise device improves recovery of forced expiratory volume in 1 second, or FEV1, from before surgery to 30 days after surgery. The study will also evaluate lung function at 90 days, symptoms, quality of life, walking capacity, training adherence, and postoperative complications.

Conditions

Non-Small Cell Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Change in Forced Expiratory Volume in 1 Second From Baseline to 30 Days After Surgery

  The primary outcome is the change in FEV1, measured in liters, from the preoperative baseline to 30 days after surgery. FEV1 will be measured using standardized pulmonary function testing. The between-group difference in the change in FEV1 will be compared.

  Baseline and 30 days after surgery

Secondary Outcomes (4)

• Change in FEV1 From Baseline to 90 Days After Surgery

  Baseline and 90 days after surgery

• Dyspnea-12 Score

  Baseline, postoperative day 1, before discharge, 1 week after surgery, and 30 days after surgery

• MD Anderson Symptom Inventory-Lung Cancer Module Score

  Baseline, 30 days after surgery, and 90 days after surgery

• Six-Minute Walk Distance

  Baseline, 30 days after surgery, and 90 days after surgery

Study Arms (2)

Experimental

EXPERIMENTAL

Participants will receive usual perioperative care and active respiratory training using an intelligent pulmonary function exercise device. The training prescription is two sessions per day, with each session consisting of 30 expiratory training repetitions and 30 inspiratory training repetitions, during hospitalization and at home until 30 days after surgery. The device records training completion and parameters, provides reminders and real-time feedback, and transmits data to the study center for adherence monitoring and remote management.

Device: Intelligent Pulmonary Function Exercise Device

Usual Care and Natural Recovery Group

ACTIVE COMPARATOR

Participants will receive usual perioperative care, standard discharge education, safety instructions, and natural recovery follow-up. No study-specified respiratory training device, prescribed number of respiratory training sessions, or dynamic training targets will be provided. Any self-initiated respiratory training, use of respiratory training devices, or pulmonary rehabilitation outside the study will be recorded during follow-up.

Behavioral: Usual Care and Natural Recovery

Interventions

Intelligent Pulmonary Function Exercise Device DEVICE

Participants will receive usual perioperative care and active respiratory training using an intelligent pulmonary function exercise device. The training prescription is two sessions per day, with each session consisting of 30 expiratory training repetitions and 30 inspiratory training repetitions, during hospitalization and at home until 30 days after surgery. The device records training completion and parameters, provides reminders and real-time feedback, and transmits data to the study center for adherence monitoring and remote management.

Experimental

Usual Care and Natural Recovery BEHAVIORAL

Participants will receive usual perioperative care, standard discharge education, safety instructions, and natural recovery follow-up. No study-specified respiratory training device, prescribed number of respiratory training sessions, or dynamic training targets will be provided. Any self-initiated respiratory training, use of respiratory training devices, or pulmonary rehabilitation outside the study will be recorded during follow-up.

Usual Care and Natural Recovery Group

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Age 18 to 75 years. 2. Pathologically confirmed primary non-small cell lung cancer. 3. Scheduled to undergo elective thoracoscopic lobectomy or sublobar resection. 4. Able to understand the study and voluntarily sign written informed consent before surgery.
• \. Able to communicate and complete study assessments and postoperative follow-up.
• \. Able to use a smartphone independently or with assistance from a caregiver for training records.
• \. Good lung re-expansion on postoperative chest imaging. 8. No chest tube drainage or no persistent air leak from chest tube drainage. 9. Clinical stage cT1-T2b, N0-N1, M0, stage IA-IIB. 10. Home environment allows safe training.

You may not qualify if:

• \. Preoperative measured FEV1 less than 50% of predicted value. 2. Severe cardiopulmonary dysfunction or other conditions judged unsuitable for respiratory training.
• \. Previous thoracic surgery or major thoracic trauma. 4. Significant cognitive impairment or psychiatric disorder that prevents cooperation with the study.
• \. Pregnancy or breastfeeding. 6. Recent severe infection or active pulmonary disease.

Sponsors & Collaborators

• The First Affiliated Hospital of Guangzhou Medical University: lead

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Jianxing He, MD

CONTACT

020-83062810; jianxinghe@gzhmu.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Participants and intervention providers cannot be blinded because of the nature of the behavioral and device-based intervention. Outcome assessors and statistical analysts will remain blinded to group allocation until completion of the primary analysis.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Participants will be randomized in a 1:1 ratio to receive either intelligent pulmonary function exercise device-guided pulmonary rehabilitation or usual care with natural recovery after lung cancer surgery.

Study Record Dates

• First Submitted: June 2, 2026
• First Posted: June 8, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): August 1, 2028
• Study Completion (Estimated): December 1, 2028
• Last Updated: June 8, 2026

Record last verified: 2026-05